

hearing on this question must be accompanied by a statement of the reasons a written presentation would not suffice in lieu of a hearing, identifying specifically any questions of fact that are in dispute, summarizing the evidence that would be presented at a hearing, and indicating how the party commenting would be aggrieved by approval of the proposal.

Comments regarding the application must be received at the Reserve Bank indicated or the offices of the Board of Governors not later than March 7, 1995.

A. Federal Reserve Bank of Chicago (James A. Bluemle, Vice President) 230 South LaSalle Street, Chicago, Illinois 60690:

1. *Quad City Holdings, Inc.*, Bettendorf, Iowa; to engage *de novo* through its subsidiary Quad City Bancorp, Inc. Bettendorf, Iowa, in the transfer of merchant credit card operation, pursuant to § 225.25(b)(1) of the Board's Regulation Y.

Board of Governors of the Federal Reserve System, February 14, 1995.

William W. Wiles,

Secretary of the Board.

[FR Doc. 95-4139 Filed 2-17-95; 8:45 am]

BILLING CODE 6210-01-F

Werner E. Schreiber Blind Trust, et al.; Change in Bank Control Notices; Acquisitions of Shares of Banks or Bank Holding Companies

The notificants listed below have applied under the Change in Bank Control Act (12 U.S.C. 1817(j)) and § 225.41 of the Board's Regulation Y (12 CFR 225.41) to acquire a bank or bank holding company. The factors that are considered in acting on the notices are set forth in paragraph 7 of the Act (12 U.S.C. 1817(j)(7)).

The notices are available for immediate inspection at the Federal Reserve Bank indicated. Once the notices have been accepted for processing, they will also be available for inspection at the offices of the Board of Governors. Interested persons may express their views in writing to the Reserve Bank indicated for that notice or to the offices of the Board of Governors. Comments must be received not later than March 7, 1995.

A. Federal Reserve Bank of Minneapolis (James M. Lyon, Vice President) 250 Marquette Avenue, Minneapolis, Minnesota 55480:

1. *Werner E. Schreiber Blind Trust; and Marlene I. Havens, Larry W. Jochim, and Jerry J. James as co-trustee*, all of Whitefish, Montana; all to acquire 22.89 percent of the voting shares of Flathead Holding Company, Bigfork, Montana,

and thereby indirectly acquire Flathead Bank of Bigfork, Bigfork, Montana.

In addition Applicants also propose to acquire a total of 73.95 percent of the voting shares of Mountain Bank System, Inc., Whitefish, Montana, and thereby indirectly acquire Mountain Bank, Whitefish, Montana, and Valley Bank of Belgrade, Belgrade, Montana.

Board of Governors of the Federal Reserve System, February 14, 1995.

William W. Wiles,

Secretary of the Board.

[FR Doc. 95-4138 Filed 2-17-95; 8:45 am]

BILLING CODE 6210-01-F

Wilson and Muir Bancorp, Inc., et al.; Acquisitions of Companies Engaged in Permissible Nonbanking Activities

The organizations listed in this notice have applied under § 225.23(a)(2) or (f) of the Board's Regulation Y (12 CFR 225.23(a)(2) or (f)) for the Board's approval under section 4(c)(8) of the Bank Holding Company Act (12 U.S.C. 1843(c)(8)) and § 225.21(a) of Regulation Y (12 CFR 225.21(a)) to acquire or control voting securities or assets of a company engaged in a nonbanking activity that is listed in § 225.25 of Regulation Y as closely related to banking and permissible for bank holding companies. Unless otherwise noted, such activities will be conducted throughout the United States.

Each application is available for immediate inspection at the Federal Reserve Bank indicated. Once the application has been accepted for processing, it will also be available for inspection at the offices of the Board of Governors. Interested persons may express their views in writing on the question whether consummation of the proposal can "reasonably be expected to produce benefits to the public, such as greater convenience, increased competition, or gains in efficiency, that outweigh possible adverse effects, such as undue concentration of resources, decreased or unfair competition, conflicts of interests, or unsound banking practices." Any request for a hearing on this question must be accompanied by a statement of the reasons a written presentation would not suffice in lieu of a hearing, identifying specifically any questions of fact that are in dispute, summarizing the evidence that would be presented at a hearing, and indicating how the party commenting would be aggrieved by approval of the proposal.

Unless otherwise noted, comments regarding each of these applications must be received at the Reserve Bank indicated for the application or the

offices of the Board of Governors not later than March 7, 1995.

A. Federal Reserve Bank of St. Louis (Randall C. Sumner, Vice President) 411 Locust Street, St. Louis, Missouri 63166:

1. *Wilson and Muir Bancorp, Inc.*, Bardstown, Kentucky; to acquire Bankers Mortgage Corporation, Louisville, Kentucky, and thereby engage in the business of originating and making loans secured by mortgages on, or deeds of trust relating to, real property, pursuant to § 225.25(b)(1) of the Board's Regulation Y.

B. Federal Reserve Bank of Minneapolis (James M. Lyon, Vice President) 250 Marquette Avenue, Minneapolis, Minnesota 55480:

1. *First Community Bancorp, Inc.*, Glasgow, Montana; to acquire First National Agency, Hinsdale, Montana, and thereby engage in operating a general insurance agency in a town with a population of less than 5,000, pursuant to § 225.25(b)(8)(iii)(A) of the Board's Regulation Y.

Board of Governors of the Federal Reserve System, February 14, 1995.

William W. Wiles,

Secretary of the Board.

[FR Doc. 95-4140 Filed 2-17-95; 8:45 am]

BILLING CODE 6210-01-F

HARRY S TRUMAN SCHOLARSHIP FOUNDATION

Harry S Truman Scholarship 1995 Supplemental Competition

AGENCY: Harry S Truman Scholarship Foundation.

ACTION: Notice of closing date for Supplemental Nominations from Eligible Institutions of Higher Education.

SUMMARY: Notice is hereby given that, pursuant to the authority contained in the Harry S Truman Memorial Scholarship Act, Public Law 93-642 (20 U.S.C. 2001), nominations are being accepted from eligible institutions of higher education for 1995 Truman Scholarships. Procedures are prescribed in 45 CFR 1801 (August 22, 1994; vol. 59, no. 161 sec. 13).

In order to be assured consideration, all documentation in support of nominations for the supplemental competition must be received by the Truman Scholarship Review Committee, 2255 N. Dubuque Road, P.O. Box 168, Iowa City, IA 52243 no later than March 31, 1995, from participating two- and four-year institutions.

Dated: February 10, 1995.

Louis H. Blair,

Executive Secretary.

[FR Doc. 95-4091 Filed 2-17-95; 8:45 am]

BILLING CODE BOAC-95001-M

DEPARTMENT OF HEALTH AND HUMAN SERVICES

Food and Drug Administration

[Docket No. 94N-0357]

Surveillance System for Antimicrobial Resistance; Public Hearing; Reopening of Comment Period

AGENCY: Food and Drug Administration, HHS.

ACTION: Notice; reopening of comment period.

SUMMARY: The Food and Drug Administration (FDA) is reopening to April 1, 1995, the comment period for the notice of public hearing regarding approaches to surveillance for the development of bacterial resistance to human and animal antimicrobial drugs, which published in the **Federal Register** of October 14, 1994 (59 FR 52168). Interested persons were given until February 1, 1995, to submit comments. FDA is taking this action to provide interested persons with an opportunity to comment on submissions received after the public hearing.

DATES: Submit written comments by April 1, 1995.

ADDRESSES: Submit written comments to the Dockets Management Branch (HFA-305), Food and Drug Administration, rm. 1-23, 12420 Parklawn Dr., Rockville, MD 20857. Two copies of any comments are to be submitted, except that individuals may submit one copy. Comments are to be identified with docket number found in brackets in the heading of this document. Received comments may be seen in the Dockets Management Branch between 9 a.m. and 4 p.m., Monday through Friday. Transcripts of the November 9 and 10, 1994, hearing are available for review at the Dockets Management Branch (address above).

FOR FURTHER INFORMATION CONTACT: Ermona McGoodwin, Center for Drug Evaluation and Research (HFD-9), Food and Drug Administration, 5600 Fishers Lane, Rockville, MD 20857, 301-443-5455.

SUPPLEMENTARY INFORMATION: In the **Federal Register** of October 14, 1994 (59 FR 52168), FDA announced that it would be holding a public hearing November 9 and 10, 1994, on

surveillance systems for antimicrobial resistance. Interested persons were given until February 1, 1995, to submit comments. The purpose of the hearing was to solicit information from, and the views of, interested persons, including scientists, professional groups, and consumers, on the issues and concerns relating to approaches for regulatory purposes to surveillance for the development of bacterial resistance to antibacterial agents used in humans and in animals. This hearing was held in response to a recommendation for improved surveillance for the development of antimicrobial resistance in both animals and humans as discussed at the May 11 and 12, 1994, joint meeting of FDA's Anti-Infective Drugs Advisory Committee and the Veterinary Medicine Advisory Committee (see the **Federal Register** of April 15, 1994, (59 FR 18136 at 18137)).

FDA is actively seeking the views of professional and consumer groups regarding the implications of an animal and human bacterial resistance monitoring system for regulatory purposes on their constituent populations. To permit time for all interested persons to comment on submissions received after the public hearing, the administrative record of the hearing will remain open until April 1, 1995. Persons who wish to provide additional materials for consideration should file these materials with the Dockets Management Branch (address above) by April 1, 1995.

Dated: February 14, 1995.

William B. Schultz,

Deputy Commissioner for Policy.

[FR Doc. 95-4213 Filed 2-17-95; 8:45 am]

BILLING CODE 4160-01-F

National Institutes of Health

National Institute of Environmental Health Sciences; Notice of Closed Meeting

Pursuant to Section 10(d) of the Federal Advisory Committee Act, as amended (5 U.S.C. Appendix 2), notice is hereby given of the following meeting:

Name of Committee: Environmental Health Sciences Review Committee

Date: March 27-29, 1995.

Time: 8:30 a.m. to Adjournment.

Place: National Institute of Environmental Health Sciences, Building 101 Conference Room, South Campus, Research Triangle Park, North Carolina.

Contact Person: Dr. Ethel Jackson, Scientific Review Administrator, P.O. Box 12233, Research Triangle Park, NC 27709, (919) 541-7826.

Purpose: To review and evaluate grant applications.

The meeting will be closed in accordance with the provisions set forth in secs. 552b(c)(4) and 552b(c)(6), Title 5, U.S.C. Applications and the discussions could reveal confidential trade secrets or commercial property such as patentable material, and personal information concerning individuals associated with the applications, the disclosure of which would constitute a clearly unwarranted invasion of personal privacy.

(Catalog of Federal Domestic Assistance Program Nos. 93.113, Biological Response to Environmental Health Hazards; 93.114, Applied Toxicological Research and Testing; 93.115, Biometry and Risk Estimation; 93.894, Research and Manpower Development, National Institutes of Health.)

Dated: February 14, 1995.

Susan K. Feldman,

Committee Management Officer, NIH.

[FR Doc. 95-4114 Filed 2-17-95; 8:45 am]

BILLING CODE 4140-01-M

National Heart, Lung, and Blood Institute; Notice of Closed Meeting

Pursuant to Section 10(d) of the Federal Advisory Committee Act, as amended (5 U.S.C. Appendix 2), notice is hereby given of the following Initial Review Group (IRG) meeting:

Name of IRG: Heart, Lung, and Blood Program Project Review Committee.

Date: March 23-24, 1995.

Time: 8:00 a.m.

Place: Holiday Inn Chevy Chase, Chevy Chase, Maryland.

Contact Person: Dr. Jeffrey Hurst, 5333 Westbard Avenue, Room 555, Bethesda, Maryland 20892, (301) 594-7418.

Purpose/Agenda: To review and evaluate grant applications.

The meeting will be closed in accordance with the provisions set forth in sec. 552(b)(c)(4) and 552(c)(6), Title 5, U.S.C. Applications and the discussions could reveal confidential trade secrets or commercial property such as patentable material and personal information concerning individuals associated with the applications, the disclosure of which would constitute a clearly unwarranted invasion of personal privacy.

(Catalog of Federal Domestic Assistance Programs Nos. 93.837, Heart and Vascular Diseases Research; 93.838, Lung Diseases Research; and 93.839, Blood Diseases and Resources Research, National Institutes of Health.)

Dated: February 14, 1995.

Susan K. Feldman,

Committee Management Officer, NIH.

[FR Doc. 95-4112 Filed 2-17-95; 8:45 am]

BILLING CODE 4140-01-M